# Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment.

> PubMed lists PMID 42158165 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42158165-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42158165-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42158165-semaglutide-v1.json
- Content SHA-256: `305c63767f7cecd5b71e5f946e194caee9192b9c056bdfdc032fe5e50c0586f5`

## Claims and source pins

### Headline

Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment. ([`pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b`](#source-pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b))

### Summary

PubMed lists PMID 42158165 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b`](#source-pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b))

### Paragraph 1

PubMed lists PMID 42158165 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b`](#source-pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b`](#source-pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b))

## Sources

<a id="source-pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b"></a>
- **Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment. · retained source version 1:2026-08-13:current:ccb89642cb0b45e2091f4c302f091c0ec37fe096014974289b8bc6418e48c159** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42158165/) (`pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42158165-semaglutide-v1.json SHA-256: 305c63767f7cecd5b71e5f946e194caee9192b9c056bdfdc032fe5e50c0586f5.